Kuros News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kuros. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kuros Today - Breaking & Trending Today

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales - adhoc - Börsennachrichten

Kuros Biosciences AG Key word Quarter ResultsRegulatory Approval Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales 24Apr2024 0700 CETCEST Release of an ad ....

Kuros Biosciences , Leadership Team , Drug Administration , Business Development , Kuros Medical Devices , Magnetos Putty , Joe Ross , Senior Vice President , Chris Fair ,

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA - adhoc - Börsennachrichten

Kuros Biosciences AG Key word StudyStudy results Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials STRUCTURE and MAXA 27Dec2023 0700 CETCEST Release of an ad hoc ann ....

Kuros Biosciences , Chief Executive Officer ,

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management - adhoc - Börsennachrichten

Kuros Biosciences AG Key word Quarter Results Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management 12Oct2023 0 ....

Clemens Van Blitterswijk , Medical Devices , Executive Management , Chris Fair , Chief Executive , Chief Operating Officer , Chief Executive Officer , Executive Director , Kuros Board , Xpand Biotechnology , John Griffin , Chief Commercial Officer , Sjoerd Musters ,

Kuros Biosciences Reports Results for First Half 2023 - adhoc - Börsennachrichten

Kuros Biosciences AG Key word Half Year Results Kuros Biosciences Reports Results for First Half 2023 09Aug2023 0700 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issuer is sole ....

Kuros Biosciences , Daniel Geiger , Clinical Oral Implants Research , Chief Financial , Chief Executive Officer , Chief Financial Officer , Regenerative Medicine ,

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH 23.11.2022 / 07:00 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reporte. ....

United States , Kuros Biosciences , Michael Grau , Drug Administration , News Service , Swiss Exchange , Biosciences Completes Enrollment , Randomized Stage , Serious Adverse Events , Investigational New Drug , Chief Executive Officer , Sci Advisors , Lumbar Interbody Fusion , Stage Of , Ibrin Pth , Et Cest ,